Hinova Pharmaceuticals (SHSE:688302) Institutional Ownership: 6.33% (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
32 GF Score
Price ¥34.55
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals Institutional Ownership?

Hinova Pharmaceuticals SHSE:688302 -1.40% 32 Institutional Ownership is 6.33% as of Aug. 26, 2026. GuruFocus rates SHSE:688302 with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hinova Pharmaceuticals's institutional ownership is 6.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hinova Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hinova Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Hinova Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Hinova Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals Institutional Ownership Chart

Hinova Pharmaceuticals Historical Data

The historical data trend for Hinova Pharmaceuticals can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 8.86 8.86 6.34 6.34 6.34 6.34 6.33 6.33 6.33 6.33
SHSE:688302
32GF Score
Hinova Pharmaceuticals Inc SHSE:688302
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 6.33% mean?
Hinova Pharmaceuticals (SHSE:688302) has a Institutional Ownership of 6.33% as of Aug. 26, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hinova Pharmaceuticals and its competitors.
Is Hinova Pharmaceuticals' Institutional Ownership too high?
Hinova Pharmaceuticals' current Institutional Ownership is 6.33%. Overall, Hinova Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Institutional Ownership compare to VRTX and REGN?
Hinova Pharmaceuticals' Institutional Ownership of 6.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current Institutional Ownership is 6.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Institutional Ownership of 6.33%. The current Institutional Ownership is 6.33%. Hinova Pharmaceuticals' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Institutional Ownership is 6.33% as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
32GF Score

Get the complete analysis for SHSE:688302

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥34.55
Price